C Q Meng1, X S Zheng, L A Holt
1AtheroGenics, Inc., 8995 Westdise Parkway, 30004, Alpharetta, GA, USA. cmeng@atherogenics.com
New nitrobenzene compounds effectively inhibit VCAM-1 expression, offering potential treatments for inflammatory diseases like autoimmune and allergic conditions. Structure-activity studies confirm essential chemical features for this potent VCAM-1 inhibition.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: